Biotechnology

Cellectis entered into a lease agreement in March of 2019 to build the Innovative Manufacturing Plant for Allogeneic Cellular Therapies (IMPACT) in Raleigh, N.C. Designed by Laporte Euro, the facility will produce immunotherapies based on gene-edited allogeneic CAR T-cells (UCART). Colliers International assisted in the real estate transaction. In addition, Cellectis is building a 14,000-sf manufacturing facility in Paris.

Amicus Therapeutics is creating the Global Research and Gene Therapy Center of Excellence in Philadelphia. The 75,000-sf facility will provide collaborative laboratories and offices for the discovery and development of treatments for rare metabolic diseases. Accommodating up to 200 employees, the center will serve as the headquarters for the global Amicus science organization and the gene therapy division’s leadership team. Occupancy is expected in the second half of 2019.

Akouos, a genetic medicine company, has leased 37,500 sf in Boston for its research headquarters. The facility is located in a two-story, 150,000-sf building at 645 Summer Street and will support the discovery and commercialization of therapies for hearing disorders. The project was developed by Pappas Enterprises and renovated by Tocci Building Corporation. The sustainably designed structure has attained LEED Silver certification.

Rosalind Franklin University is building the $50 million Innovation and Research Park in North Chicago, Ill. The four-story, 100,000-sf facility will provide leading-edge research labs, business incubator space, meeting rooms, and common areas. The project will promote collaboration among faculty, industry scientists, and biotech entrepreneurs in order to accelerate the discovery and commercialization of new medical treatments and therapeutics.

Autolus Therapeutics has signed a long-term, full-building lease with Alexandria Real Estate Equities for the construction and development of a build-to-suit facility in Rockville, Md. Located in the Shady Grove Life Sciences Center, the 85,000-sf project will accommodate the company's U.S. headquarters and a commercial-scale manufacturing center for cell therapies. Occupancy is expected in 2021.

Catalent is initiating an expansion of its biologics manufacturing operations. The global biotechnology company will construct a 60,000-sf facility on its existing campus in Madison, Wis. The project is slated for completion by 2021 and represents an investment of $100 million over the next three years. Catalent will also invest $100 million to increase its manufacturing capacity in Bloomington, Ind.

Global life science company Promega is constructing a $190 million research and development center on its existing campus in Fitchburg, Wis. Offering laboratories with sophisticated infrastructure to support the creation of innovative bioscience products and technologies, the three-story, 270,000-sf facility will enable the consolidation of operations currently located in three separate buildings. Ground was broken on the project in July of 2018 and occupancy is expected in fall of 2020. 

Brammer Bio is developing two gene therapy manufacturing facilities in Massachusetts. The company will build out 35,000 sf in an existing 50,000-sf structure in Lexington to create a cGMP manufacturing and quality control operations center. Additionally, Brammer will renovate 8,000 sf in its 66,000-sf commercial cGMP plant in Cambridge to create new production suites to support manufacturing capacity expansion. DPS Group is providing architectural and engineering services for both projects, which are slated for completion in mid-2019.

16 Tech Community Corporation broke ground in December of 2018 on the $30 million Advanced Research and Innovation Facility in Indianapolis. The Indiana Biosciences Research Institute will lease over 67,000 sf on the first three floors of the building to accommodate researchers engaged in the study of diabetes, nutrition, and metabolics. Indiana University School of Medicine will locate the Center for Regenerative Medicine's molecular therapeutics program in 12,000 sf of the facility, which will also house the Central Indiana Corporate Partnership.

Mustang Bio completed construction of its 27,000-sf cell therapy manufacturing center in November of 2018. Located in the UMass Medicine Science Park in Worcester, the facility supports the clinical development and commercialization of Mustang's CAR-T and gene therapy product candidates. Accommodating proprietary cell therapy research, the project involved the renovation of labs and offices, as well as the conversion of existing labs to create three cGMP ISO7 clinical production areas.

AbbVie signed a long-term lease in November of 2018 for 480,000 sf in the Gateway of Pacific development in South San Francisco. The facility will be located in a 12-story building currently being constructed by BioMed Realty. Gateway of Pacific is being delivered in two phases, with the first phase comprising 555,000 sf of lab, research, office, and amenity space. Completion is expected in late 2019. The second phase will provide an additional 431,000 sf of lab, office, and parking space and is slated for completion in late 2021.

LA BioMed is planning to build a $63 million bioscience research facility on its existing campus in Torrance, Calif. The four-story building will include an 18,000-sf business incubator able to accommodate up to 30 companies at full capacity. The project will support the translation of research discoveries into innovative solutions and products. Occupancy is expected in February of 2019. 

The United Kingdom's Medical Research Council is planning to build the £75 million London Institute of Medical Sciences. Designed by Hawkins\Brown, the 110,000-sf project will provide collaborative biomedical research facilities including two CL-2 biocontainment labs, vibration-mitigated imaging suites, core biotechnology labs, write-up areas, and a data center. The nine-story facility is being created in partnership with Imperial College London and will accommodate up to 45 research groups currently dispersed around Hammersmith Hospital.

Atara Biotherapeutics opened a $55 million manufacturing facility in June of 2018 in Thousand Oaks, Calif. Designed by HPA Architects to meet LEED sustainable design criteria, the Atara T-cell Operations and Manufacturing (ATOM) center houses a 90,000-sf facility for the production of CAR-T allogeneic therapies, as well as additional R&D labs and offices. The project was developed by Sares-Regis Group with Atara signing a 15-year lease for the building.

Valent Biosciences opened the 85,000-sf Biorational Research Center in July of 2018 in Libertyville, Ill. Sited adjacent to the company's existing headquarters, the facility offers 65,000 sf of open lab space designed to foster collaborative research and development. The facility features a state-of-the-art 20,000-sf greenhouse to support the creation of innovative agricultural products and technologies. Valent Biosciences is a subsidiary of Sumitomo Chemical Company Health and Crop Sciences.